nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—SST—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.00565	0.028	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—HNF1B—kidney cancer	0.00506	0.0251	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—KCNMA1—kidney cancer	0.00493	0.0245	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—IL13—kidney cancer	0.00474	0.0235	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—JUND—kidney cancer	0.00442	0.0219	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—SCARB1—kidney cancer	0.00429	0.0213	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CD34—kidney cancer	0.00376	0.0187	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.00366	0.0181	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.00359	0.0178	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—OR4C13—kidney cancer	0.00357	0.0177	CbGpPWpGaD
Cysteamine—NPY2R—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.00351	0.0174	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—SCARB1—kidney cancer	0.00349	0.0173	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—OR4C13—kidney cancer	0.00342	0.017	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—OR4C13—kidney cancer	0.00324	0.0161	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—OR4C13—kidney cancer	0.00311	0.0154	CbGpPWpGaD
Cysteamine—SST—G alpha (i) signalling events—ANXA1—kidney cancer	0.00308	0.0153	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—ANXA1—kidney cancer	0.00296	0.0147	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—SOD2—kidney cancer	0.0029	0.0144	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—EGR1—kidney cancer	0.00281	0.014	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—SCARB1—kidney cancer	0.00278	0.0138	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS1—kidney cancer	0.00275	0.0136	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.0025	0.0124	CbGpPWpGaD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.00245	0.0122	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—SOD2—kidney cancer	0.00236	0.0117	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.00235	0.0117	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—RELA—kidney cancer	0.00217	0.0108	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—CD4—kidney cancer	0.00212	0.0105	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—IL2—kidney cancer	0.00195	0.00969	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—GSTM1—kidney cancer	0.00194	0.00962	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—OR4C13—kidney cancer	0.00191	0.0095	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—SOD2—kidney cancer	0.00187	0.0093	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—ANXA1—kidney cancer	0.00187	0.00927	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—OR4C13—kidney cancer	0.00183	0.0091	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—POMC—kidney cancer	0.00179	0.00889	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—ANXA1—kidney cancer	0.00179	0.00889	CbGpPWpGaD
Cysteamine—NPY2R—Peptide ligand-binding receptors—POMC—kidney cancer	0.00172	0.00852	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—RELA—kidney cancer	0.00168	0.00832	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—LATS1—kidney cancer	0.00163	0.00807	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—LATS1—kidney cancer	0.00156	0.00774	CbGpPWpGaD
Cysteamine—SST—G alpha (i) signalling events—POMC—kidney cancer	0.00151	0.0075	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—JUN—kidney cancer	0.00151	0.00749	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.0015	0.00743	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—AKAP13—kidney cancer	0.00148	0.00735	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—POMC—kidney cancer	0.00145	0.00719	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—KIT—kidney cancer	0.00144	0.00714	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AKAP13—kidney cancer	0.00142	0.00705	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AMER1—kidney cancer	0.00138	0.00687	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—RELA—kidney cancer	0.00136	0.00677	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AKAP13—kidney cancer	0.00134	0.00668	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—AMER1—kidney cancer	0.00133	0.00658	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.00132	0.00654	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—PIK3CA—kidney cancer	0.0013	0.00643	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AKAP13—kidney cancer	0.00129	0.0064	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—ITPR2—kidney cancer	0.00126	0.00625	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—IL2—kidney cancer	0.00123	0.0061	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—ITPR2—kidney cancer	0.00121	0.00599	CbGpPWpGaD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.0012	0.00596	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—JUN—kidney cancer	0.00118	0.00586	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—kidney cancer	0.00117	0.0058	CbGpPWpGaD
Cysteamine—Leukopenia—Vincristine—kidney cancer	0.00116	0.00146	CcSEcCtD
Cysteamine—Urethral disorder—Paclitaxel—kidney cancer	0.00116	0.00145	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GPC3—kidney cancer	0.00116	0.00575	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CER1—kidney cancer	0.00116	0.00575	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.00115	0.00572	CbGpPWpGaD
Cysteamine—Dyspepsia—Sorafenib—kidney cancer	0.00115	0.00144	CcSEcCtD
Cysteamine—Abdominal pain—Erlotinib—kidney cancer	0.00114	0.00143	CcSEcCtD
Cysteamine—Body temperature increased—Erlotinib—kidney cancer	0.00114	0.00143	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—ITPR2—kidney cancer	0.00114	0.00568	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—PTEN—kidney cancer	0.00114	0.00567	CbGpPWpGaD
Cysteamine—Anaemia—Gemcitabine—kidney cancer	0.00114	0.00143	CcSEcCtD
Cysteamine—Decreased appetite—Sorafenib—kidney cancer	0.00113	0.00142	CcSEcCtD
Cysteamine—Anorexia—Dactinomycin—kidney cancer	0.00113	0.00142	CcSEcCtD
Cysteamine—Nausea—Pazopanib—kidney cancer	0.00113	0.00141	CcSEcCtD
Cysteamine—Convulsion—Vincristine—kidney cancer	0.00113	0.00141	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00112	0.00141	CcSEcCtD
Cysteamine—Fatigue—Sorafenib—kidney cancer	0.00112	0.00141	CcSEcCtD
Cysteamine—Hypertension—Vincristine—kidney cancer	0.00112	0.0014	CcSEcCtD
Cysteamine—Constipation—Sorafenib—kidney cancer	0.00111	0.00139	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GPC3—kidney cancer	0.00111	0.00552	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CER1—kidney cancer	0.00111	0.00552	CbGpPWpGaD
Cysteamine—Hypersensitivity—Vinblastine—kidney cancer	0.00111	0.00139	CcSEcCtD
Cysteamine—Hypersensitivity—Everolimus—kidney cancer	0.00111	0.00138	CcSEcCtD
Cysteamine—Dyspepsia—Sunitinib—kidney cancer	0.0011	0.00138	CcSEcCtD
Cysteamine—Leukopenia—Gemcitabine—kidney cancer	0.0011	0.00138	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CD4—kidney cancer	0.0011	0.00546	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—ITPR2—kidney cancer	0.0011	0.00544	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—kidney cancer	0.00109	0.00542	CbGpPWpGaD
Cysteamine—Decreased appetite—Sunitinib—kidney cancer	0.00109	0.00136	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—RELA—kidney cancer	0.00108	0.00538	CbGpPWpGaD
Cysteamine—Mental disability—Doxorubicin—kidney cancer	0.00108	0.00136	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00108	0.00135	CcSEcCtD
Cysteamine—Asthenia—Vinblastine—kidney cancer	0.00108	0.00135	CcSEcCtD
Cysteamine—Fatigue—Sunitinib—kidney cancer	0.00108	0.00135	CcSEcCtD
Cysteamine—Asthenia—Everolimus—kidney cancer	0.00108	0.00135	CcSEcCtD
Cysteamine—Constipation—Sunitinib—kidney cancer	0.00107	0.00134	CcSEcCtD
Cysteamine—Immune system disorder—Paclitaxel—kidney cancer	0.00107	0.00134	CcSEcCtD
Cysteamine—Gastrointestinal pain—Sorafenib—kidney cancer	0.00107	0.00133	CcSEcCtD
Cysteamine—Renal failure—Capecitabine—kidney cancer	0.00106	0.00133	CcSEcCtD
Cysteamine—Hypertension—Gemcitabine—kidney cancer	0.00106	0.00133	CcSEcCtD
Cysteamine—Anaphylactic shock—Vincristine—kidney cancer	0.00106	0.00133	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—ANXA1—kidney cancer	0.00106	0.00524	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—kidney cancer	0.00105	0.00523	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Nervous system disorder—Vincristine—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Asthenia—Erlotinib—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Mental disorder—Paclitaxel—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—Discomfort—Gemcitabine—kidney cancer	0.00104	0.0013	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN1B—kidney cancer	0.00103	0.00514	CbGpPWpGaD
Cysteamine—Urticaria—Sorafenib—kidney cancer	0.00103	0.0013	CcSEcCtD
Cysteamine—Erythema—Paclitaxel—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Malnutrition—Paclitaxel—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Decreased appetite—Dactinomycin—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Diarrhoea—Vinblastine—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Abdominal pain—Sorafenib—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Body temperature increased—Sorafenib—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Diarrhoea—Everolimus—kidney cancer	0.00103	0.00129	CcSEcCtD
Cysteamine—Gastrointestinal pain—Sunitinib—kidney cancer	0.00102	0.00128	CcSEcCtD
Cysteamine—Fatigue—Dactinomycin—kidney cancer	0.00102	0.00128	CcSEcCtD
Cysteamine—Tension—Paclitaxel—kidney cancer	0.00101	0.00127	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—ANXA1—kidney cancer	0.00101	0.00502	CbGpPWpGaD
Cysteamine—Anorexia—Vincristine—kidney cancer	0.00101	0.00127	CcSEcCtD
Cysteamine—Anaphylactic shock—Gemcitabine—kidney cancer	0.00101	0.00126	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—kidney cancer	0.001	0.00126	CcSEcCtD
Cysteamine—Nervousness—Paclitaxel—kidney cancer	0.001	0.00125	CcSEcCtD
Cysteamine—Dizziness—Vinblastine—kidney cancer	0.000996	0.00125	CcSEcCtD
Cysteamine—Dizziness—Everolimus—kidney cancer	0.000992	0.00124	CcSEcCtD
Cysteamine—Body temperature increased—Sunitinib—kidney cancer	0.000991	0.00124	CcSEcCtD
Cysteamine—Abdominal pain—Sunitinib—kidney cancer	0.000991	0.00124	CcSEcCtD
Cysteamine—Diarrhoea—Erlotinib—kidney cancer	0.000991	0.00124	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CCND1—kidney cancer	0.000987	0.0049	CbGpPWpGaD
Cysteamine—Nervous system disorder—Gemcitabine—kidney cancer	0.000986	0.00124	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SFRP2—kidney cancer	0.000986	0.00489	CbGpPWpGaD
Cysteamine—Feeling abnormal—Dactinomycin—kidney cancer	0.000978	0.00122	CcSEcCtD
Cysteamine—Skin disorder—Gemcitabine—kidney cancer	0.000977	0.00122	CcSEcCtD
Cysteamine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00097	0.00121	CcSEcCtD
Cysteamine—Tremor—Paclitaxel—kidney cancer	0.000967	0.00121	CcSEcCtD
Cysteamine—Urinary tract disorder—Capecitabine—kidney cancer	0.00096	0.0012	CcSEcCtD
Cysteamine—Hypersensitivity—Sorafenib—kidney cancer	0.00096	0.0012	CcSEcCtD
Cysteamine—Anorexia—Gemcitabine—kidney cancer	0.000959	0.0012	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—ANXA1—kidney cancer	0.000958	0.00476	CbGpPWpGaD
Cysteamine—Vomiting—Vinblastine—kidney cancer	0.000958	0.0012	CcSEcCtD
Cysteamine—Dizziness—Erlotinib—kidney cancer	0.000957	0.0012	CcSEcCtD
Cysteamine—Connective tissue disorder—Capecitabine—kidney cancer	0.000956	0.0012	CcSEcCtD
Cysteamine—Vomiting—Everolimus—kidney cancer	0.000954	0.00119	CcSEcCtD
Cysteamine—Anaemia—Paclitaxel—kidney cancer	0.000953	0.00119	CcSEcCtD
Cysteamine—Urethral disorder—Capecitabine—kidney cancer	0.000953	0.00119	CcSEcCtD
Cysteamine—Agitation—Paclitaxel—kidney cancer	0.000948	0.00119	CcSEcCtD
Cysteamine—Rash—Everolimus—kidney cancer	0.000946	0.00118	CcSEcCtD
Cysteamine—Dermatitis—Everolimus—kidney cancer	0.000945	0.00118	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SFRP2—kidney cancer	0.000945	0.00469	CbGpPWpGaD
Cysteamine—Headache—Vinblastine—kidney cancer	0.000944	0.00118	CcSEcCtD
Cysteamine—Headache—Everolimus—kidney cancer	0.00094	0.00118	CcSEcCtD
Cysteamine—Body temperature increased—Dactinomycin—kidney cancer	0.000938	0.00117	CcSEcCtD
Cysteamine—Abdominal pain—Dactinomycin—kidney cancer	0.000938	0.00117	CcSEcCtD
Cysteamine—Asthenia—Sorafenib—kidney cancer	0.000934	0.00117	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—kidney cancer	0.000925	0.00116	CcSEcCtD
Cysteamine—Leukopenia—Paclitaxel—kidney cancer	0.000923	0.00116	CcSEcCtD
Cysteamine—Hypersensitivity—Sunitinib—kidney cancer	0.000923	0.00116	CcSEcCtD
Cysteamine—Decreased appetite—Vincristine—kidney cancer	0.000921	0.00115	CcSEcCtD
Cysteamine—Vomiting—Erlotinib—kidney cancer	0.00092	0.00115	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—ANXA1—kidney cancer	0.000919	0.00456	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000915	0.00115	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—POMC—kidney cancer	0.000915	0.00454	CbGpPWpGaD
Cysteamine—Fatigue—Vincristine—kidney cancer	0.000914	0.00114	CcSEcCtD
Cysteamine—Rash—Erlotinib—kidney cancer	0.000913	0.00114	CcSEcCtD
Cysteamine—Dermatitis—Erlotinib—kidney cancer	0.000912	0.00114	CcSEcCtD
Cysteamine—Headache—Erlotinib—kidney cancer	0.000907	0.00114	CcSEcCtD
Cysteamine—Constipation—Vincristine—kidney cancer	0.000906	0.00114	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—kidney cancer	0.000906	0.00113	CcSEcCtD
Cysteamine—Asthenia—Sunitinib—kidney cancer	0.000899	0.00113	CcSEcCtD
Cysteamine—Nausea—Vinblastine—kidney cancer	0.000895	0.00112	CcSEcCtD
Cysteamine—Somnolence—Gemcitabine—kidney cancer	0.000894	0.00112	CcSEcCtD
Cysteamine—Convulsion—Paclitaxel—kidney cancer	0.000894	0.00112	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—kidney cancer	0.000892	0.00112	CcSEcCtD
Cysteamine—Nausea—Everolimus—kidney cancer	0.000891	0.00112	CcSEcCtD
Cysteamine—Diarrhoea—Sorafenib—kidney cancer	0.000891	0.00112	CcSEcCtD
Cysteamine—Hypertension—Paclitaxel—kidney cancer	0.000891	0.00112	CcSEcCtD
Cysteamine—Immune system disorder—Capecitabine—kidney cancer	0.000878	0.0011	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—POMC—kidney cancer	0.000877	0.00435	CbGpPWpGaD
Cysteamine—Decreased appetite—Gemcitabine—kidney cancer	0.000874	0.00109	CcSEcCtD
Cysteamine—Hypersensitivity—Dactinomycin—kidney cancer	0.000874	0.00109	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000872	0.00109	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000868	0.00109	CcSEcCtD
Cysteamine—Discomfort—Paclitaxel—kidney cancer	0.000868	0.00109	CcSEcCtD
Cysteamine—Fatigue—Gemcitabine—kidney cancer	0.000867	0.00109	CcSEcCtD
Cysteamine—Gastrointestinal pain—Vincristine—kidney cancer	0.000867	0.00109	CcSEcCtD
Cysteamine—Dizziness—Sorafenib—kidney cancer	0.000861	0.00108	CcSEcCtD
Cysteamine—Constipation—Gemcitabine—kidney cancer	0.00086	0.00108	CcSEcCtD
Cysteamine—Nausea—Erlotinib—kidney cancer	0.00086	0.00108	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—kidney cancer	0.000858	0.00108	CcSEcCtD
Cysteamine—Diarrhoea—Sunitinib—kidney cancer	0.000857	0.00107	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—kidney cancer	0.000852	0.00107	CcSEcCtD
Cysteamine—Mental disorder—Capecitabine—kidney cancer	0.000852	0.00107	CcSEcCtD
Cysteamine—Asthenia—Dactinomycin—kidney cancer	0.000851	0.00107	CcSEcCtD
Cysteamine—Confusional state—Paclitaxel—kidney cancer	0.000849	0.00106	CcSEcCtD
Cysteamine—Erythema—Capecitabine—kidney cancer	0.000847	0.00106	CcSEcCtD
Cysteamine—Malnutrition—Capecitabine—kidney cancer	0.000847	0.00106	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—kidney cancer	0.000843	0.00106	CcSEcCtD
Cysteamine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000842	0.00105	CcSEcCtD
Cysteamine—Abdominal pain—Vincristine—kidney cancer	0.000838	0.00105	CcSEcCtD
Cysteamine—Body temperature increased—Vincristine—kidney cancer	0.000838	0.00105	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—kidney cancer	0.000837	0.00105	CcSEcCtD
Cysteamine—Dizziness—Sunitinib—kidney cancer	0.000829	0.00104	CcSEcCtD
Cysteamine—Feeling abnormal—Gemcitabine—kidney cancer	0.000829	0.00104	CcSEcCtD
Cysteamine—Vomiting—Sorafenib—kidney cancer	0.000828	0.00104	CcSEcCtD
Cysteamine—Nervous system disorder—Paclitaxel—kidney cancer	0.000826	0.00103	CcSEcCtD
Cysteamine—Rash—Sorafenib—kidney cancer	0.000821	0.00103	CcSEcCtD
Cysteamine—Dermatitis—Sorafenib—kidney cancer	0.00082	0.00103	CcSEcCtD
Cysteamine—Skin disorder—Paclitaxel—kidney cancer	0.000818	0.00102	CcSEcCtD
Cysteamine—Headache—Sorafenib—kidney cancer	0.000816	0.00102	CcSEcCtD
Cysteamine—Diarrhoea—Dactinomycin—kidney cancer	0.000812	0.00102	CcSEcCtD
Cysteamine—Anorexia—Paclitaxel—kidney cancer	0.000803	0.00101	CcSEcCtD
Cysteamine—Vomiting—Sunitinib—kidney cancer	0.000797	0.000998	CcSEcCtD
Cysteamine—Body temperature increased—Gemcitabine—kidney cancer	0.000795	0.000996	CcSEcCtD
Cysteamine—SST—Signaling Pathways—AKAP13—kidney cancer	0.000795	0.00394	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CASP2—kidney cancer	0.000795	0.00394	CbGpPWpGaD
Cysteamine—Tremor—Capecitabine—kidney cancer	0.000793	0.000993	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—MYC—kidney cancer	0.000792	0.00393	CbGpPWpGaD
Cysteamine—Rash—Sunitinib—kidney cancer	0.00079	0.00099	CcSEcCtD
Cysteamine—Dermatitis—Sunitinib—kidney cancer	0.000789	0.000989	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—kidney cancer	0.000789	0.00391	CbGpPWpGaD
Cysteamine—Headache—Sunitinib—kidney cancer	0.000785	0.000983	CcSEcCtD
Cysteamine—Anaemia—Capecitabine—kidney cancer	0.000782	0.00098	CcSEcCtD
Cysteamine—Hypersensitivity—Vincristine—kidney cancer	0.000781	0.000978	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—kidney cancer	0.000779	0.00387	CbGpPWpGaD
Cysteamine—Nausea—Sorafenib—kidney cancer	0.000774	0.000969	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—AKAP13—kidney cancer	0.000762	0.00378	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CASP2—kidney cancer	0.000762	0.00378	CbGpPWpGaD
Cysteamine—Asthenia—Vincristine—kidney cancer	0.000761	0.000952	CcSEcCtD
Cysteamine—Leukopenia—Capecitabine—kidney cancer	0.000758	0.000949	CcSEcCtD
Cysteamine—Vomiting—Dactinomycin—kidney cancer	0.000754	0.000945	CcSEcCtD
Cysteamine—Somnolence—Paclitaxel—kidney cancer	0.000748	0.000937	CcSEcCtD
Cysteamine—Rash—Dactinomycin—kidney cancer	0.000748	0.000937	CcSEcCtD
Cysteamine—Nausea—Sunitinib—kidney cancer	0.000744	0.000932	CcSEcCtD
Cysteamine—Dyspepsia—Paclitaxel—kidney cancer	0.000741	0.000928	CcSEcCtD
Cysteamine—Decreased appetite—Paclitaxel—kidney cancer	0.000732	0.000917	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—kidney cancer	0.000732	0.00363	CbGpPWpGaD
Cysteamine—Hypertension—Capecitabine—kidney cancer	0.000731	0.000915	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000727	0.00091	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GRB7—kidney cancer	0.000727	0.00361	CbGpPWpGaD
Cysteamine—Fatigue—Paclitaxel—kidney cancer	0.000726	0.000909	CcSEcCtD
Cysteamine—Diarrhoea—Vincristine—kidney cancer	0.000725	0.000908	CcSEcCtD
Cysteamine—Asthenia—Gemcitabine—kidney cancer	0.000721	0.000904	CcSEcCtD
Cysteamine—Constipation—Paclitaxel—kidney cancer	0.00072	0.000902	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000716	0.000896	CcSEcCtD
Cysteamine—Discomfort—Capecitabine—kidney cancer	0.000712	0.000892	CcSEcCtD
Cysteamine—Nausea—Dactinomycin—kidney cancer	0.000705	0.000883	CcSEcCtD
Cysteamine—Dizziness—Vincristine—kidney cancer	0.000701	0.000878	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GRB7—kidney cancer	0.000697	0.00346	CbGpPWpGaD
Cysteamine—Confusional state—Capecitabine—kidney cancer	0.000697	0.000872	CcSEcCtD
Cysteamine—Feeling abnormal—Paclitaxel—kidney cancer	0.000694	0.000869	CcSEcCtD
Cysteamine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000688	0.000862	CcSEcCtD
Cysteamine—Diarrhoea—Gemcitabine—kidney cancer	0.000688	0.000862	CcSEcCtD
Cysteamine—Renal failure—Doxorubicin—kidney cancer	0.000686	0.00086	CcSEcCtD
Cysteamine—Nervous system disorder—Capecitabine—kidney cancer	0.000678	0.000849	CcSEcCtD
Cysteamine—SST—Signaling Pathways—ITPR2—kidney cancer	0.000676	0.00335	CbGpPWpGaD
Cysteamine—Vomiting—Vincristine—kidney cancer	0.000674	0.000844	CcSEcCtD
Cysteamine—Skin disorder—Capecitabine—kidney cancer	0.000671	0.00084	CcSEcCtD
Cysteamine—Urticaria—Paclitaxel—kidney cancer	0.000669	0.000838	CcSEcCtD
Cysteamine—Rash—Vincristine—kidney cancer	0.000668	0.000837	CcSEcCtD
Cysteamine—Dermatitis—Vincristine—kidney cancer	0.000668	0.000836	CcSEcCtD
Cysteamine—Body temperature increased—Paclitaxel—kidney cancer	0.000666	0.000834	CcSEcCtD
Cysteamine—Abdominal pain—Paclitaxel—kidney cancer	0.000666	0.000834	CcSEcCtD
Cysteamine—Headache—Vincristine—kidney cancer	0.000664	0.000832	CcSEcCtD
Cysteamine—Anorexia—Capecitabine—kidney cancer	0.000659	0.000825	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—ITPR2—kidney cancer	0.000648	0.00321	CbGpPWpGaD
Cysteamine—Vomiting—Gemcitabine—kidney cancer	0.000639	0.000801	CcSEcCtD
Cysteamine—Rash—Gemcitabine—kidney cancer	0.000634	0.000794	CcSEcCtD
Cysteamine—Dermatitis—Gemcitabine—kidney cancer	0.000633	0.000793	CcSEcCtD
Cysteamine—Headache—Gemcitabine—kidney cancer	0.00063	0.000789	CcSEcCtD
Cysteamine—Nausea—Vincristine—kidney cancer	0.00063	0.000789	CcSEcCtD
Cysteamine—Hypersensitivity—Paclitaxel—kidney cancer	0.00062	0.000777	CcSEcCtD
Cysteamine—Urinary tract disorder—Doxorubicin—kidney cancer	0.000619	0.000775	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—kidney cancer	0.000616	0.000771	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—kidney cancer	0.000615	0.00077	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CTNNA1—kidney cancer	0.000612	0.00304	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HSPB1—kidney cancer	0.000609	0.00302	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EIF4EBP1—kidney cancer	0.000609	0.00302	CbGpPWpGaD
Cysteamine—Dyspepsia—Capecitabine—kidney cancer	0.000608	0.000762	CcSEcCtD
Cysteamine—Asthenia—Paclitaxel—kidney cancer	0.000604	0.000756	CcSEcCtD
Cysteamine—Decreased appetite—Capecitabine—kidney cancer	0.000601	0.000752	CcSEcCtD
Cysteamine—Nausea—Gemcitabine—kidney cancer	0.000597	0.000748	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000597	0.000747	CcSEcCtD
Cysteamine—Fatigue—Capecitabine—kidney cancer	0.000596	0.000746	CcSEcCtD
Cysteamine—Constipation—Capecitabine—kidney cancer	0.000591	0.00074	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CTNNA1—kidney cancer	0.000587	0.00291	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EIF4EBP1—kidney cancer	0.000584	0.0029	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HSPB1—kidney cancer	0.000584	0.0029	CbGpPWpGaD
Cysteamine—Diarrhoea—Paclitaxel—kidney cancer	0.000576	0.000721	CcSEcCtD
Cysteamine—Feeling abnormal—Capecitabine—kidney cancer	0.000569	0.000713	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—kidney cancer	0.000566	0.000709	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PSMD7—kidney cancer	0.000566	0.00281	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ANXA1—kidney cancer	0.000566	0.00281	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TSC1—kidney cancer	0.000566	0.00281	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000565	0.000708	CcSEcCtD
Cysteamine—Dizziness—Paclitaxel—kidney cancer	0.000557	0.000697	CcSEcCtD
Cysteamine—Mental disorder—Doxorubicin—kidney cancer	0.000549	0.000688	CcSEcCtD
Cysteamine—Urticaria—Capecitabine—kidney cancer	0.000549	0.000687	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FLT1—kidney cancer	0.000548	0.00272	CbGpPWpGaD
Cysteamine—Body temperature increased—Capecitabine—kidney cancer	0.000546	0.000684	CcSEcCtD
Cysteamine—Abdominal pain—Capecitabine—kidney cancer	0.000546	0.000684	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—kidney cancer	0.000546	0.000683	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—kidney cancer	0.000546	0.000683	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—ANXA1—kidney cancer	0.000543	0.00269	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PSMD7—kidney cancer	0.000543	0.00269	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TSC1—kidney cancer	0.000543	0.00269	CbGpPWpGaD
Cysteamine—Tension—Doxorubicin—kidney cancer	0.000536	0.000671	CcSEcCtD
Cysteamine—Vomiting—Paclitaxel—kidney cancer	0.000535	0.00067	CcSEcCtD
Cysteamine—Rash—Paclitaxel—kidney cancer	0.000531	0.000665	CcSEcCtD
Cysteamine—Dermatitis—Paclitaxel—kidney cancer	0.00053	0.000664	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—kidney cancer	0.00053	0.000664	CcSEcCtD
Cysteamine—Headache—Paclitaxel—kidney cancer	0.000527	0.000661	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—FLT1—kidney cancer	0.000526	0.00261	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—POMC—kidney cancer	0.000517	0.00257	CbGpPWpGaD
Cysteamine—Hypersensitivity—Capecitabine—kidney cancer	0.000509	0.000637	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PAK1—kidney cancer	0.000508	0.00252	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—JUNB—kidney cancer	0.000508	0.00252	CbGpPWpGaD
Cysteamine—Anaemia—Doxorubicin—kidney cancer	0.000504	0.000632	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—kidney cancer	0.000501	0.000628	CcSEcCtD
Cysteamine—Nausea—Paclitaxel—kidney cancer	0.0005	0.000626	CcSEcCtD
Cysteamine—Asthenia—Capecitabine—kidney cancer	0.000496	0.000621	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—POMC—kidney cancer	0.000496	0.00246	CbGpPWpGaD
Cysteamine—Leukopenia—Doxorubicin—kidney cancer	0.000488	0.000612	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—JUNB—kidney cancer	0.000487	0.00242	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PAK1—kidney cancer	0.000487	0.00242	CbGpPWpGaD
Cysteamine—Convulsion—Doxorubicin—kidney cancer	0.000473	0.000592	CcSEcCtD
Cysteamine—Diarrhoea—Capecitabine—kidney cancer	0.000473	0.000592	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—kidney cancer	0.000471	0.00059	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—POMC—kidney cancer	0.000469	0.00233	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000461	0.000578	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—kidney cancer	0.000459	0.000575	CcSEcCtD
Cysteamine—Dizziness—Capecitabine—kidney cancer	0.000457	0.000572	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—POMC—kidney cancer	0.00045	0.00223	CbGpPWpGaD
Cysteamine—Confusional state—Doxorubicin—kidney cancer	0.000449	0.000562	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000445	0.000558	CcSEcCtD
Cysteamine—Vomiting—Capecitabine—kidney cancer	0.000439	0.00055	CcSEcCtD
Cysteamine—Nervous system disorder—Doxorubicin—kidney cancer	0.000437	0.000547	CcSEcCtD
Cysteamine—Rash—Capecitabine—kidney cancer	0.000436	0.000546	CcSEcCtD
Cysteamine—Dermatitis—Capecitabine—kidney cancer	0.000435	0.000545	CcSEcCtD
Cysteamine—Headache—Capecitabine—kidney cancer	0.000433	0.000542	CcSEcCtD
Cysteamine—Skin disorder—Doxorubicin—kidney cancer	0.000433	0.000542	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—kidney cancer	0.000425	0.000532	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IGF2—kidney cancer	0.000416	0.00206	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN2B—kidney cancer	0.000414	0.00205	CbGpPWpGaD
Cysteamine—Nausea—Capecitabine—kidney cancer	0.00041	0.000514	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IGF1R—kidney cancer	0.000402	0.00199	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IGF2—kidney cancer	0.000398	0.00198	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN2B—kidney cancer	0.000397	0.00197	CbGpPWpGaD
Cysteamine—Somnolence—Doxorubicin—kidney cancer	0.000396	0.000496	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—kidney cancer	0.000392	0.000491	CcSEcCtD
Cysteamine—Decreased appetite—Doxorubicin—kidney cancer	0.000387	0.000485	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—RAF1—kidney cancer	0.000387	0.00192	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IGF1R—kidney cancer	0.000385	0.00191	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000385	0.000482	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—kidney cancer	0.000384	0.000481	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—IL2—kidney cancer	0.000382	0.0019	CbGpPWpGaD
Cysteamine—Constipation—Doxorubicin—kidney cancer	0.000381	0.000477	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—RAF1—kidney cancer	0.000371	0.00184	CbGpPWpGaD
Cysteamine—Feeling abnormal—Doxorubicin—kidney cancer	0.000367	0.00046	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—IL2—kidney cancer	0.000366	0.00182	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000364	0.000456	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—kidney cancer	0.000354	0.000443	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—kidney cancer	0.000352	0.000441	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—kidney cancer	0.000352	0.000441	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—IL2—kidney cancer	0.000347	0.00172	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—IL2—kidney cancer	0.000333	0.00165	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HIF1A—kidney cancer	0.000331	0.00164	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TSC2—kidney cancer	0.00033	0.00164	CbGpPWpGaD
Cysteamine—Hypersensitivity—Doxorubicin—kidney cancer	0.000328	0.000411	CcSEcCtD
Cysteamine—Asthenia—Doxorubicin—kidney cancer	0.00032	0.0004	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—HIF1A—kidney cancer	0.000317	0.00157	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KDR—kidney cancer	0.000316	0.00157	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TSC2—kidney cancer	0.000316	0.00157	CbGpPWpGaD
Cysteamine—Diarrhoea—Doxorubicin—kidney cancer	0.000305	0.000382	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—KDR—kidney cancer	0.000303	0.00151	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—kidney cancer	0.000295	0.000369	CcSEcCtD
Cysteamine—SST—Signaling Pathways—KIT—kidney cancer	0.000291	0.00145	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—APC—kidney cancer	0.000291	0.00145	CbGpPWpGaD
Cysteamine—Vomiting—Doxorubicin—kidney cancer	0.000283	0.000355	CcSEcCtD
Cysteamine—Rash—Doxorubicin—kidney cancer	0.000281	0.000352	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—kidney cancer	0.000281	0.000351	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—KIT—kidney cancer	0.000279	0.00139	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—APC—kidney cancer	0.000279	0.00139	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—MAPK3—kidney cancer	0.000279	0.00138	CbGpPWpGaD
Cysteamine—Headache—Doxorubicin—kidney cancer	0.000279	0.000349	CcSEcCtD
Cysteamine—SST—Signaling Pathways—POMC—kidney cancer	0.000277	0.00138	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—BRAF—kidney cancer	0.000274	0.00136	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—MAPK3—kidney cancer	0.000268	0.00133	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—POMC—kidney cancer	0.000266	0.00132	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—MAPK1—kidney cancer	0.000266	0.00132	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—kidney cancer	0.000265	0.000331	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—BRAF—kidney cancer	0.000263	0.0013	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—MAPK1—kidney cancer	0.000255	0.00126	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CA—kidney cancer	0.000254	0.00126	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—KRAS—kidney cancer	0.000251	0.00124	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CA—kidney cancer	0.000243	0.00121	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—kidney cancer	0.00024	0.00119	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CA—kidney cancer	0.00023	0.00114	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—RAF1—kidney cancer	0.000229	0.00113	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—RELA—kidney cancer	0.000228	0.00113	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ERBB2—kidney cancer	0.000226	0.00112	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MTOR—kidney cancer	0.000223	0.00111	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CA—kidney cancer	0.000221	0.0011	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—RAF1—kidney cancer	0.000219	0.00109	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—RELA—kidney cancer	0.000218	0.00108	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ERBB2—kidney cancer	0.000217	0.00108	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MTOR—kidney cancer	0.000214	0.00106	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN1B—kidney cancer	0.00021	0.00104	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IL2—kidney cancer	0.000205	0.00102	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN1B—kidney cancer	0.000201	0.000997	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCND1—kidney cancer	0.0002	0.000992	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—JUN—kidney cancer	0.000199	0.00099	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CTNNB1—kidney cancer	0.000198	0.000982	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IL2—kidney cancer	0.000197	0.000976	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTEN—kidney cancer	0.000193	0.000958	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCND1—kidney cancer	0.000192	0.000951	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—JUN—kidney cancer	0.000191	0.000949	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CTNNB1—kidney cancer	0.00019	0.000942	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTEN—kidney cancer	0.000185	0.000918	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—VEGFA—kidney cancer	0.000174	0.000865	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—VEGFA—kidney cancer	0.000167	0.000829	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MAPK3—kidney cancer	0.000165	0.000818	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MYC—kidney cancer	0.00016	0.000796	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MAPK3—kidney cancer	0.000158	0.000784	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MAPK1—kidney cancer	0.000157	0.000778	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MYC—kidney cancer	0.000154	0.000763	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MAPK1—kidney cancer	0.00015	0.000746	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—kidney cancer	0.000148	0.000735	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—kidney cancer	0.000142	0.000705	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CA—kidney cancer	0.000136	0.000675	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—kidney cancer	0.000132	0.000653	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CA—kidney cancer	0.00013	0.000648	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—kidney cancer	0.000126	0.000627	CbGpPWpGaD
